WHO Sounds Warning Over Acute Scarcity of Weight-Loss Jabs

Less than one in 10 patients who could benefit from obesity jabs like Wegovy have access to them, warns the WHO as it issues its first recommendations on the drugs.

Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for more widespread and fairer access to GLP-1 medication.

According to estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention.

"Our latest guidelines affirms that obesity is a long-term condition that can be treated with holistic and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and distribution challenges are key hurdles to broad access to the jabs that can assist patients in reducing substantial body mass, notes the body.

Skinny Jab Scarcity

Even in the current best projected case, the manufacturing of these medications would only suffice for approximately 100 million people – less than 10% of the global need, per the health organization.

The guideline encourages countries and companies to widen access, by approaches including licensing agreements.

A patent on the active ingredient – the main component of the drug Wegovy – is set to lapse in multiple countries in 2026.

How Obesity Jabs Operate

GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals consume fewer calories.

People commonly begin shedding pounds in the initial weeks of starting on the regular doses.

Studies indicates people may see weight return after a year of stopping the medication, because their typical appetite come back.

To be carrying excess weight elevates your risk for developing diseases, such as diabetes, cardiovascular issues, brain attack, and specific cancers.

Excess weight affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, as per the WHO.